Reformulated Gout Drug Protects Against Cardiac Events
The U.S. Food & Drug Administration has approved colchicine (Lodoco®) for reducing cardiovascular (CVD) events in patients with atherosclerosis or at high CVD risk. The first anti-inflammatory drug approved for this purpose, Lodoco is taken daily with or without a statin or other lipid-lowering drug.
The post Heart Beat – September 2023 appeared first on Heart Advisor.